ArticleCureus2025
Mesenchymal Stromal Cell Treatment Alleviates Autism Spectrum Disorder Symptoms: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is associated with significant lifelong challenges for severely affected children and their families. The condition remains poorly understood, and no reliable, effective treatments are available. Presented is a case of a boy with severe ASD, epilepsy, and a pathological electroencephalogram (EEG) who underwent five treatments between the ages of 5.75 years and nine years with mesenchymal stem cells from allogeneic placenta and umbilical cord tissue of unrelated donors. A significant clinical response was observed following each course, including the disappearance of seizures, normalization of the EEG after the first course, and continuously improved ASD symptoms, social skills, and emotional expression. Allogeneic mesenchymal stem cells might offer an attractive innovative modality for some children with ASD and may prove a promising therapy for children with seizure disorders. Clinical research directions are presented to develop these innovative treatments and design future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.